Fundraising Fox

Eleven Biotherapeutics

Cambridge, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

SH
Stephen HurlyExecutive
JM
John McCabeExecutive
AP
Arthur P. DeCillisExecutive
DA
David A. BerryNamed on SEC filing
GD
Gregory D. PerryNamed on SEC filing
ES
Eric S. FurfineNamed on SEC filing
PC
Paul ChaneyNamed on SEC filing
KL
Karen L. TurbridyNamed on SEC filing
CG
Cary G. PfefferNamed on SEC filing

Board

DS
Daniel S. LynchBoard director
AC
Abbie C. Celniker, Ph.D.Board director
PG
Paul G. ChaneyBoard director

Investors · 1

Third Rock VenturesreportedBoston · $100K – $5Mvia Abbie Celniker · board

Reported raises · per SEC filings

Form D private placements

$34.5M disclosed across 3 rounds · 2014–2018

▶$996KraisedApr 2018 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry J. GertzDirector
  • Richard F. FitzgeraldExecutive Officer
  • Leslie DanDirector
  • Jane V. HendersonDirector
  • Wendy L. DixonDirector
  • Paul G. ChaneyDirector
  • Stephen A. HurlyExecutive Officer, Director
  • Abbie C. CelnikerDirector
  • Jay S. DukerDirector
  • Daniel S. LynchDirector
Offering amount
$996K
Amount sold
$996K
Sales commissions
$36.1K
Finders' fees
$30.9K
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedSep 2016 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel S. LynchDirector
  • Paul G. ChaneyDirector
  • Stephen HurlyExecutive Officer, Director
  • John McCabeExecutive Officer
  • Jay S. DukerDirector
  • Wendy L. DixonDirector
  • Barry J. GertzDirector
  • Abbie C. Celniker, Ph.D.Director
  • Leslie DanDirector
  • Jane V. HendersonDirector
  • Arthur P. DeCillisExecutive Officer
Offering amount
$13.5M
Amount sold
$13.5M
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedDec 2014 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David A. BerryExecutive Officer, Director
  • Gregory D. PerryExecutive Officer
  • Daniel S. LynchDirector
  • Eric S. FurfineExecutive Officer
  • Abbie C. Celniker, Ph.D.Executive Officer, Director
  • Paul ChaneyDirector
  • Jane V. HendersonDirector
  • Karen L. TurbridyExecutive Officer
  • Cary G. PfefferDirector
  • Wendy L. DixonDirector
Offering amount
$20M
Amount sold
$20M
Sales commissions
$1.4M
Placement agents
Cowen and Company, LLC, Leerink Partners LLC, Citigroup Global Markets Inc.
First sale
Dec 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Eleven Biotherapeutics's investors?
Eleven Biotherapeutics's investors include Third Rock Ventures.
How much funding has Eleven Biotherapeutics raised?
Eleven Biotherapeutics has disclosed $34.5M raised across 3 rounds.
Where is Eleven Biotherapeutics headquartered?
Eleven Biotherapeutics is headquartered in Cambridge, US.